行情

GNCA

GNCA

Genocea
NASDAQ

实时行情|Nasdaq Last Sale

3.010
0.000
0.00%
盘后: 3.000 -0.01 -0.33% 19:12 08/07 EDT
开盘
2.990
昨收
3.010
最高
3.100
最低
2.985
成交量
51.85万
成交额
--
52周最高
5.75
52周最低
1.100
市值
9,019.31万
市盈率(TTM)
-2.0539
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测

分析师预测GNCA价格均价为9.40，最高价位18.00，最低价为5.00。

EPS

GNCA 新闻

更多
AstraZeneca Nirsevimab Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/31 17:07
Mid-Afternoon Market Update: Nasdaq Turns Higher; Kraton Shares Plummet
Toward the end of trading Thursday, the Dow traded down 0.98% to 26280.13 while the NASDAQ rose 0.37% to 10582.30. The S&P also fell, dropping 0.49% to 3,242.49.
Benzinga · 07/30 18:32
BLNK, PEIX, GTX and BEP among midday movers
Seeking Alpha · 07/30 16:42
Mid-Day Market Update: Crude Oil Down 3%; At Home Group Shares Spike Higher
Midway through trading Thursday, the Dow traded down 1.20% to 26221.54 while the NASDAQ rose 0.01% to 10,543.55. The S&P also fell, dropping 0.76% to 3,233.65.
Benzinga · 07/30 16:17
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 07/30 15:04
Mid-Morning Market Update: Markets Open Lower; Procter & Gamble Tops Q4 Views
Following the market opening Thursday, the Dow traded down 1.81% to 26060.12 while the NASDAQ fell 0.85% to 10453.02. The S&P also fell, dropping 1.39% to 3,213.22.
Benzinga · 07/30 14:15
Genocea Biosciences Earlier Reported Will Present Prelim. Data For Neoantigen Vaccine GEN-009 In Combo With Checkpoint Inhibitors: '3 of 5 patients achieved separate RECIST responses after GEN-009 administration'
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present initial clinical data today on the first five patients from Part B of the ongoing
Benzinga · 07/30 13:56
Genocea under pressure on underwhelming neoantigen vaccine data
Seeking Alpha · 07/30 13:17

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

GNCA 简况

Genocea Biosciences, Inc.是一家开发个体化癌症免疫疗法的生物制药公司。该公司的Antigen Lead Acquisition System（ATLAS）技术平台可根据每个人的肿瘤抗原特异性T细胞反应识别靶标。通过ATLAS，该公司可以改善新抗原使其纳入免疫疗法，并排除对抗肿瘤免疫反应产生免疫抑制作用的抑制性抗原。它提供GEN-009项目，这是一种新抗原疫苗的候选者。该公司正在进行各种实体瘤类型的1/2a期临床试验。该公司还提供一种新抗原特异性的过继T细胞疗法GEN-011。
展开

微牛提供Genocea Biosciences Inc(NASDAQ-GNCA)的股票价格，实时市场报价，专业分析师评级，深度图表和免费的GNCA股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GNCA股票基本功能。